Key facts
- Verinetics’s last known valuation is $5.4M (Mar 2025).
- It has raised $2.5M across 1 recorded rounds; the latest was Seed Round ($907K) in Feb 2022.
- Notable investors include NC Idea, First Flight Venture Center, National Institute on Drug Abuse (NIDA).
- Verinetics has filed 3 Form Ds with the SEC since 2023, most recently Mar 2025 ($135K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Verinetics
Funding rounds
1 roundsAbout Verinetics
Developer of medical device technology solutions to facilitate packaging, distribution, and control of high-risk prescription medications. The company offers solutions supporting medications for opioid use disorder (MOUD) and Opioid Treatment Programs (OTPs) that can increase access to treatment and develop virtual supervision using an end-to-end solution that integrates into the client's existing patient management practices, providing patients with a tool to better monitor and control dosing at home.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2009
- Employees
- 8
- Website
- verinetics.com/
- Ownership
- Privately Held (backing)
Verinetics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Verinetics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Verinetics in its N-PORT filings yet. We sweep new filings monthly.